Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1993 Jun;109(2):518–523. doi: 10.1111/j.1476-5381.1993.tb13600.x

On the high affinity binding site for [3H]-1,3-dipropyl-8-cyclopentylxanthine in frog brain membranes.

J C Oliveira 1, A M Sebastião 1, J A Ribeiro 1
PMCID: PMC2175663  PMID: 8358551

Abstract

1. Radioligand binding properties of the adenosine receptor ligands, [3H]-1,3-dipropyl-8-cyclopentylxanthine ([3H]-DPCPX), and [3H]-R-phenylisopropyladenosine ([3H]-R-PIA) were investigated in frog brain membranes. 2. The specific binding of the adenosine antagonist, [3H]-DPCPX to frog brain membranes showed one binding site with Kd and Bmax values of 43.8 nM and 0.238 +/- 0.016 pmol mg-1 protein, respectively. Guanosine 5'-triphosphate (GTP, 100 microM) decreased to 72 +/- 7% and Mg2+ (8 mM) increased to 121 +/- 3% [3H]-DPCPX (40 nM) binding to frog brain membranes. 3. [3H]-DPCPX saturation binding experiments performed in the presence of Mg2+ (8 mM), or in the presence of GTP showed that Mg2+ ions decreased the Kd value of [3H]-DPCPX to 14 nM, and GTP increased this value to 65.6 nM. Bmax values were not significantly (P > 0.05) modified (0.261 +/- 0.018 pmol mg-1 protein, with Mg2+, and 0.266 +/- 0.026 pmol mg-1 protein, in presence of GTP) by the presence of Mg2+ or GTP. 4. The specific binding of [3H]-R-PIA (15 nM) was decreased to 37 +/- 6% by GTP (100 microM) and increased to 123 +/- 4% by Mg2+ (8 mM). [3H]-R-PIA saturation binding experiments performed in the presence of Mg2+ (8 mM) showed one binding site with Kd and Bmax values of 0.9 nM and 0.229 +/- 0.008 pmol mg-1 of protein, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
518

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexander S. P., Kendall D. A., Hill S. J. Differences in the adenosine receptors modulating inositol phosphates and cyclic AMP accumulation in mammalian cerebral cortex. Br J Pharmacol. 1989 Dec;98(4):1241–1248. doi: 10.1111/j.1476-5381.1989.tb12670.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bruns R. F., Fergus J. H., Badger E. W., Bristol J. A., Santay L. A., Hartman J. D., Hays S. J., Huang C. C. Binding of the A1-selective adenosine antagonist 8-cyclopentyl-1,3-dipropylxanthine to rat brain membranes. Naunyn Schmiedebergs Arch Pharmacol. 1987 Jan;335(1):59–63. doi: 10.1007/BF00165037. [DOI] [PubMed] [Google Scholar]
  3. Bruns R. F., Lu G. H., Pugsley T. A. Characterization of the A2 adenosine receptor labeled by [3H]NECA in rat striatal membranes. Mol Pharmacol. 1986 Apr;29(4):331–346. [PubMed] [Google Scholar]
  4. Burgisser E., De Lean A., Lefkowitz R. J. Reciprocal modulation of agonist and antagonist binding to muscarinic cholinergic receptor by guanine nucleotide. Proc Natl Acad Sci U S A. 1982 Mar;79(6):1732–1736. doi: 10.1073/pnas.79.6.1732. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. De Lean A., Hancock A. A., Lefkowitz R. J. Validation and statistical analysis of a computer modeling method for quantitative analysis of radioligand binding data for mixtures of pharmacological receptor subtypes. Mol Pharmacol. 1982 Jan;21(1):5–16. [PubMed] [Google Scholar]
  6. Gilman A. G. G proteins: transducers of receptor-generated signals. Annu Rev Biochem. 1987;56:615–649. doi: 10.1146/annurev.bi.56.070187.003151. [DOI] [PubMed] [Google Scholar]
  7. Jarvis M. F., Schulz R., Hutchison A. J., Do U. H., Sills M. A., Williams M. [3H]CGS 21680, a selective A2 adenosine receptor agonist directly labels A2 receptors in rat brain. J Pharmacol Exp Ther. 1989 Dec;251(3):888–893. [PubMed] [Google Scholar]
  8. Klotz K. N., Vogt H., Tawfik-Schlieper H. Comparison of A1 adenosine receptors in brain from different species by radioligand binding and photoaffinity labelling. Naunyn Schmiedebergs Arch Pharmacol. 1991 Feb;343(2):196–201. doi: 10.1007/BF00168610. [DOI] [PubMed] [Google Scholar]
  9. Lohse M. J., Klotz K. N., Lindenborn-Fotinos J., Reddington M., Schwabe U., Olsson R. A. 8-Cyclopentyl-1,3-dipropylxanthine (DPCPX)--a selective high affinity antagonist radioligand for A1 adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol. 1987 Aug;336(2):204–210. doi: 10.1007/BF00165806. [DOI] [PubMed] [Google Scholar]
  10. Martins M. A., Pasquale C. P., e Silva P. M., Pires A. L., Ruffié C., Rihoux J. P., Cordeiro R. S., Vargaftig B. B. Interference of cetirizine with the late eosinophil accumulation induced by either PAF or compound 48/80. Br J Pharmacol. 1992 Jan;105(1):176–180. doi: 10.1111/j.1476-5381.1992.tb14231.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Munson P. J., Rodbard D. Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem. 1980 Sep 1;107(1):220–239. doi: 10.1016/0003-2697(80)90515-1. [DOI] [PubMed] [Google Scholar]
  12. Oliveira J. C., Sebastião A. M., Ribeiro J. A. Solubilized rat brain adenosine receptors have two high-affinity binding sites for 1,3-dipropyl-8-cyclopentylxanthine. J Neurochem. 1991 Oct;57(4):1165–1171. doi: 10.1111/j.1471-4159.1991.tb08275.x. [DOI] [PubMed] [Google Scholar]
  13. Peterson G. L. A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal Biochem. 1977 Dec;83(2):346–356. doi: 10.1016/0003-2697(77)90043-4. [DOI] [PubMed] [Google Scholar]
  14. Ribeiro J. A., Sebastião A. M. Adenosine receptors and calcium: basis for proposing a third (A3) adenosine receptor. Prog Neurobiol. 1986;26(3):179–209. doi: 10.1016/0301-0082(86)90015-8. [DOI] [PubMed] [Google Scholar]
  15. Ribeiro J. A., Sebastião A. M. On the type of receptor involved in the inhibitory action of adenosine at the neuromuscular junction. Br J Pharmacol. 1985 Apr;84(4):911–918. doi: 10.1111/j.1476-5381.1985.tb17385.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Ruegg U. T., Cuenod S., Hiller J. M., Gioannini T., Howells R. D., Simon E. J. Characterization and partial purification of solubilized active opiate receptors from toad brain. Proc Natl Acad Sci U S A. 1981 Jul;78(7):4635–4638. doi: 10.1073/pnas.78.7.4635. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Sebastião A. M., Ribeiro J. A. 1,3,8- and 1,3,7-substituted xanthines: relative potency as adenosine receptor antagonists at the frog neuromuscular junction. Br J Pharmacol. 1989 Jan;96(1):211–219. doi: 10.1111/j.1476-5381.1989.tb11802.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Sebastião A. M., Stone T. W., Ribeiro J. A. The inhibitory adenosine receptor at the neuromuscular junction and hippocampus of the rat: antagonism by 1,3,8-substituted xanthines. Br J Pharmacol. 1990 Oct;101(2):453–459. doi: 10.1111/j.1476-5381.1990.tb12729.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Simon J., Szücs M., Benyhe S., Borsodi A., Zeman P., Wollemann M. Solubilization and characterization of opioid binding sites from frog (Rana esculenta) brain. J Neurochem. 1984 Oct;43(4):957–963. doi: 10.1111/j.1471-4159.1984.tb12830.x. [DOI] [PubMed] [Google Scholar]
  20. Ukena D., Jacobson K. A., Padgett W. L., Ayala C., Shamim M. T., Kirk K. L., Olsson R. O., Daly J. W. Species differences in structure-activity relationships of adenosine agonists and xanthine antagonists at brain A1 adenosine receptors. FEBS Lett. 1986 Dec 1;209(1):122–128. doi: 10.1016/0014-5793(86)81096-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Ukena D., Poeschla E., Schwabe U. Guanine nucleotide and cation regulation of radioligand binding to Ri adenosine receptors of rat fat cells. Naunyn Schmiedebergs Arch Pharmacol. 1984 Jun;326(3):241–247. doi: 10.1007/BF00505325. [DOI] [PubMed] [Google Scholar]
  22. Weber R. G., Jones C. R., Lohse M. J., Palacios J. M. Autoradiographic visualization of A1 adenosine receptors in rat brain with [3H]8-cyclopentyl-1,3-dipropylxanthine. J Neurochem. 1990 Apr;54(4):1344–1353. doi: 10.1111/j.1471-4159.1990.tb01968.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES